Cephea Early Feasibility Study (NCT05061004)
🩺 Plain-English Summary (8th-Grade Level)
The objective of this study is to evaluate the preliminary safety and effectiveness of the Cephea Mitral Valve System for the treatment of symptomatic patients with mitral valve disease (including mitral regurgitation, mitral stenosis and mixed mitral valve disease) in whom transcatheter therapy is deemed more appropriate than open heart surgery.
Who can join: Review the eligibility criteria below.
Location: Banner-University Medical Center Phoenix — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (22 Sites)
- Banner-University Medical Center Phoenix — Phoenix, Arizona
- Cedars-Sinai Medical Center — Los Angeles, California
- University of California - Davis Medical Center — Sacramento, California
- Los Robles Regional Medical Center — Thousand Oaks, California
- Emory University Hospital — Atlanta, Georgia
- Piedmont Heart Institute — Atlanta, Georgia
- Northwestern Memorial Hospital — Chicago, Illinois
- Ascension Via Christi Hospitals Wichita — Wichita, Kansas
- University of Michigan - Davis Medical Center — Ann Arbor, Michigan
- Minneapolis Heart Institute — Minneapolis, Minnesota
- New York-Presbyterian/Columbia University Medical Center — New York, New York
- Montefiore Medical Center - Moses Campus — The Bronx, New York
- Atrium Health - Carolinas Medical Center — Charlotte, North Carolina
- The Cleveland Clinic Foundation — Cleveland, Ohio
- Allegheny General Hospital - ASRI — Pittsburgh, Pennsylvania
- Ascension Saint Thomas — Nashville, Tennessee
- Vanderbilt Heart & Vascular Institute — Nashville, Tennessee
- Houston Methodist — Houston, Texas
- Sentara Norfolk General Hospital — Norfolk, Virginia
- Swedish Medical Center — Seattle, Washington
- Institut de Cardiologie de Montreal — Montreal, Quebec
- IUCPQ-ULaval — Québec, Quebec
📞 Contact the Study Coordinator
Phone: (818) 294-3041
Email: leslie.centeno@abbott.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Mitral Regurgitation
- Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation — Birmingham, Alabama
- SAPIEN M3 EFS: Early Feasibility Study of the Edwards SAPIEN M3 System for the Treatment of Mitral Regurgitation — Los Angeles, California
- Beating Heart Mitral Valve Repair With the HARPOON™ System — San Francisco, California
- Prospective Treatment Algorithm Guiding Repair of Severe Ischemic Mitral Regurgitation — Ottawa, Ontario
- LEFT ATRIAL MONITORING IN PATIENTS BEFORE AND AFTER MITRAL SURGERY - LAMBDA STUDY — Ottawa, Ontario
- CHoice of OptImal transCatheter trEatment for Mitral Insufficiency Registry — Tucson, Arizona
Explore by condition: All Mitral Regurgitation clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.